GP2-Targeting Monoclonal Antibody 2G1 for Broad Ebola Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Ebola virus treatments, particularly monoclonal antibody drugs, are limited in their ability to target a broad spectrum of ebolaviruses, with only a few drugs effective against Zaire Ebola virus, leaving a significant portion of outbreaks unaddressed.
Innovation Solution
Development of a monoclonal antibody, 2G1, with unique CDR regions that exhibit excellent sub-nanomolar affinity to Ebola virus glycoprotein GP2, capable of binding to multiple ebolaviruses, including EBOV, BDBV, SUDV, and RESTV, with a high affinity constant and stable binding across different pH conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibody drugs are developed to treat Ebola virus, then treatment effectiveness against Zaire Ebola virus is improved, but broad-spectrum coverage against other ebolaviruses deteriorates
Solution Approach 1:
The monoclonal antibody 2G1 is designed to recognize and bind to a conserved epitope on the GP2 subunit of glycoprotein across multiple ebolavirus species. This universal binding capability allows a single antibody to neutralize different ebolaviruses (EBOV, SUDV, BDBV, RESTV) simultaneously, achieving broad-spectrum coverage while maintaining high treatment effectiveness through consistent mechanism of action
Solution Approach 2:
The antibody 2G1 achieves broad-spectrum neutralization by targeting a specific parameter (conserved epitope on GP2 subunit) that remains relatively unchanged across different ebolavirus species. By focusing on this conserved region rather than variable regions, the antibody maintains reliable binding and neutralization effectiveness across diverse viral strains
2Reliability
If monoclonal antibodies with high affinity to GP are developed, then neutralization capability is improved, but binding stability across different pH conditions deteriorates
Solution Approach 1:
The antibody 2G1 maintains both high neutralization capability and binding stability by targeting an epitope on the GP2 subunit that exhibits structural conservation across different pH conditions. The binding interface is designed to accommodate pH variations through appropriate amino acid interactions, ensuring the antibody remains effective from neutral pH in circulation to acidic pH in endosomes where viral entry occurs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
2G1 demonstrates nearly 100% protection against EBOV, BDBV, and SUDV pseudoviruses in vitro and provides complete protection in animal challenge experiments, showing potential for broad-spectrum neutralization and cocktail therapy with other antibodies.
Implementation Method 1
an isolated monoclonal antibody that specifically binds to Ebola virus glycoprotein GP2 subunit
Data Source
AI summary
Disclosed is a monoclonal antibody 2G1 against an Ebola glycoprotein GP2 subunit. The monoclonal antibody has binding activity to EBOV GP, BDBV GP, SUDV GP, and RESTV GP, and can play a neutralizing role.